GSK plc
GSK
$46.63
-$0.47-1.00%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.54% | 7.26% | 1.39% | 3.93% | 1.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.54% | 7.26% | 1.39% | 3.93% | 1.08% |
| Cost of Revenue | -0.35% | 11.14% | -0.21% | 11.87% | 6.44% |
| Gross Profit | 14.98% | 5.89% | 1.95% | 0.68% | -0.96% |
| SG&A Expenses | 8.07% | -0.30% | 3.39% | 3.65% | -3.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -28.29% | -80.90% | -18.40% | 130.93% | 66.86% |
| Total Operating Expenses | 5.34% | 5.61% | 0.99% | 15.58% | 8.20% |
| Operating Income | 23.10% | 11.23% | 2.29% | -39.57% | -12.80% |
| Income Before Tax | 3,876.38% | 33.66% | 54.52% | 53.15% | -96.33% |
| Income Tax Expenses | 32,429.43% | 33.61% | 21.80% | 436.43% | -100.40% |
| Earnings from Continuing Operations | 3,317.84% | 33.66% | 62.81% | 29.78% | -95.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -10.36% | -64.09% | -320.00% | -86.87% | -80.60% |
| Net Income | 3,696.29% | 30.27% | 54.21% | 21.95% | -104.07% |
| EBIT | 23.10% | 11.23% | 2.29% | -39.57% | -12.80% |
| EBITDA | 10.78% | 28.69% | 11.44% | -18.37% | 1.33% |
| EPS Basic | 3,737.30% | 30.76% | 53.47% | 21.18% | -104.05% |
| Normalized Basic EPS | 26.19% | 7.24% | -5.06% | -49.27% | -16.79% |
| EPS Diluted | 3,678.92% | 30.43% | 53.68% | 20.94% | -104.10% |
| Normalized Diluted EPS | 25.96% | 7.10% | -5.19% | -49.29% | -16.86% |
| Average Basic Shares Outstanding | -1.13% | -0.39% | 0.47% | 0.62% | 0.62% |
| Average Diluted Shares Outstanding | -0.94% | -0.29% | 0.58% | 0.70% | 0.71% |
| Dividend Per Share | 10.50% | 12.95% | 5.94% | 3.12% | 10.10% |
| Payout Ratio | 1.03% | -0.18% | -0.31% | -0.09% | -28.24% |